Energex System's Experimental Non-Pharmacological Treatment Shown to
Reduce Viral Load in Hepatitis C Patients
Monday March 28, 5:46 pm ET
Company Plans HIV/AIDS Trial

EMERSON, N.J.--(BUSINESS WIRE)--March 28, 2005--Energex Systems, Inc.
announced today that a clinical trial has established that its
HemoModulator technology was safe and highly effective in reducing
viral loads in trial participants inflicted with Hepatitis C. There
were no reported adverse events related to the treatment. The trial was
conducted under an Investigational Device Exemption (IDE) that was
granted by the Federal Food and Drug Administration (FDA) in October,
2004.
Energex's experimental treatment involves exposing a very small amount
of an infected subjects blood (3-4%) to a very precise amount of
ultra-violet light in the C band (UVC), for a very precise amount of
time, explained Thomas Petrie, the developer of the technology and
Director of Engineering at Energex Systems. "After exposure the treated
blood is returned to the patient through the same portal it was drawn
from. The result, we believe, is a stimulation of the immune system",
said Petrie. The process takes 20-30 minutes.

In the trial, non-responders to Interferon/Ribaviran with a viral load
of at least 100,000 IU or more were administered PCR tests before
treatment, on days 1,8, and 15. The average of the tests is the
baseline that post-treatment tests are compared to. After the blood
draw on day 15, the 1st treatment is administered, followed by the 2nd
treatment on day 17. Prior to the 3rd treatment on day 20, the first
post-treatment PCR test is administered and the result is compared to
the baseline. The 4th and 5th treatments are administered on days 25
and 30 respectively. On day 33 the 1st PCR test after the last
treatment is administered and compared to the baseline. Additional PCR
tests are administered on days 57, 64 and 71 and the average of the
tests is compared to the baseline.

As an example of the effectiveness of the therapy as established in the
trial, the Company reported that three subjects (3 of 10) had sustained
viral load reductions of 90% or greater at 10 weeks post treatment and
eight had sustained reductions of 50% or greater. Only two subjects did
not respond to the therapy.

"We are encouraged by the results of this trial, particularly, the
rapid and dramatic viral load reductions we saw and the fact that there
were no reported adverse events related to the therapy", said Thomas J.
Fagan, President of Energex Systems. Hepatitis C is just the beginning.
Preliminary laboratory work we have done on SIV/HIV/AIDS suggests that
this therapy will be effective in treating those viruses. It is our
intention to seek approval from the Federal Food and Drug
Administration (FDA) through an Investigation Device Exemption (IDE) to
conduct a trial on humans inflicted with HIV/AIDS. We are excited about
the potential that our technology has to manage these hard-to-treat
diseases, to reduce the cost of care, and to provide a better quality
of life for the millions that suffer from them. We are committed to
expending whatever resources are necessary to see that this technology
continues through the research and approval processes, and that it is
accepted by the medical community as the treatment of choice for these
potentially life threatening diseases," said Fagan.

Energex Systems is dedicated to developing medical technologies and
therapies with an emphasis on the treatment of conditions unmet by
present day therapies and reducing the cost of care.

                                                                 Ron